UEEC · XBRL financial data

United Health Products financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (UEEC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	0	0*	0	0	0	0*	0	0	0	0*	0	0
Cost of goods and services sold	0	0*	—	—	—	—	—	—	—	—	—	—
Gross profit	0	0*	—	—	—	—	—	—	—	—	—	—
Research and development	122	153*	116	66	66	109*	116	81	25	47*	13	4
Selling, general and administrative	329	293*	310	339	326	677*	1,373	187	208	217*	253	163
Total operating expenses	450	447*	425	405	392	785*	1,489	268	233	265*	266	167
Operating income (loss)	(450)	(447)*	(425)	(405)	(392)	(785)*	(1,489)	(268)	(233)	(265)*	(266)	(167)
Interest expense	16	8*	8	8	8	9*	21	25	31	37*	48	50
Other income (expense)	(35)	(25)*	(27)	(27)	88	(29)*	(42)	(47)	(52)	(272)*	(50)	(117)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(486)	(472)*	(452)	(432)	(304)	(814)*	(1,532)	(315)	(286)	(537)*	(316)	(284)
Earnings per share, basic USD per share	0.00	—	—	—	—	—	—	—	—	—	—	—
Earnings per share, diluted USD per share	0.00	—	0.00	0.00	0.00	0.00*	(0.01)	0.00	0.00	0.00*	0.00	0.00
Weighted average shares, basic thousands of shares	241,486	—	—	—	—	—	—	—	—	—	—	—
Weighted average shares, diluted thousands of shares	241,486	243,135*	245,751	247,718	248,615	250,578*	254,577	257,140	257,810	258,348*	258,690	260,041

Fiscal quarters (UEEC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	74	95	81	19	44	169	5	0	18	65	1	24
Inventory	34	34	34	0	0	0	—	—	—	—	—	—
Prepaid and other current assets	30	23	15	8	20	23	30	21	25	40	46	40
Total current assets	138	152	130	26	64	192	35	21	43	105	47	65
Right-of-use asset	83	77	69	62	55	47	39	31	23	15	6	0
Total assets	336	285	233	122	151	270	105	82	94	317	249	248
Accrued liabilities	169	226	276	325	—	—	—	—	—	—	—	—
Total current liabilities	2,063	1,950	1,989	2,091	2,235	1,641	1,806	1,905	2,006	3,943	4,191	4,188
Lease liability, non-current	55	48	40	33	26	15	6	0	0	0	0	0
Total liabilities	2,118	1,999	2,029	2,124	2,262	2,714	2,960	3,252	3,434	4,193	4,441	4,691
Accumulated deficit	(76,227)	(76,699)	(77,151)	(77,583)	(77,887)	(78,701)	(80,233)	(80,548)	(80,833)	(81,370)	(81,686)	(82,079)
Total stockholders' equity	(1,783)	(1,714)	(1,796)	(2,002)	(2,111)	(2,444)	(2,855)	(3,171)	(3,340)	(3,876)	(4,192)	(4,443)
Total liabilities and equity	336	285	233	122	151	270	105	82	94	317	249	248
Common shares outstanding (cover page) thousands of shares	242,983	246,833	247,933	248,433	250,083	252,408	257,133	257,733	258,690	258,690	260,386	262,686

Fiscal quarters (UEEC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(486)	(472)*	(452)	(432)	(304)	(814)*	(1,532)	(315)	(286)	(537)*	(316)	(284)
Stock-based compensation	—	—	—	—	—	—	—	—	0*	—	—	—
Net cash from operating activities	(605)*	(577)*	(406)	(288)*	(320)*	(181)*	(274)	(185)*	(175)*	(553)*	(84)	(138)*
Net cash from investing activities	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Proceeds from issuing common stock	571*	603*	395	229*	198*	—	—	—	—	—	—	—
Proceeds from issuing equity	—	year only	—	—	—	year only	—	—	—	year only	—	—
Share repurchases	—	0*	—	—	—	—	—	—	—	—	—	—
Repayments of long-term debt	0*	0*	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	545*	598*	391	226*	345*	307*	110	180*	193*	600*	20	161*

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
Vivos Therapeutics	1,774	5,153	(3,148)*	20.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Positron	357	112	(1,050)*	32.8M	0.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.